Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TARS Tarsus Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: TARS
Price (delayed)
$42.65
Market cap
$1.79B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.72
Enterprise value
$1.69B
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline
Highlights
The company's equity has surged by 53% QoQ and by 24% YoY
The company's EPS rose by 42% YoY and by 11% QoQ
The company's quick ratio rose by 30% QoQ but it fell by 30% YoY
Tarsus Pharmaceuticals's debt has surged by 140% YoY
Key stats
What are the main financial stats of TARS
Market
Valuations
Earnings
Shares outstanding
42.01M
Market cap
$1.79B
Enterprise value
$1.69B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.78
Price to sales (P/S)
7.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.22
Revenue
$233.67M
Gross profit
$217.29M
Operating income
-$109.17M
Net income
-$104.94M
EBIT
-$95.86M
EBITDA
-$93.78M
Free cash flow
-$72.87M
Per share
Balance sheet
Liquidity
EPS
-$2.72
EPS diluted
-$2.72
Free cash flow per share
-$1.85
Book value per share
$8.92
Revenue per share
$5.94
TBVPS
$12.52
Total assets
$500.75M
Total liabilities
$158.29M
Debt
$71.98M
Equity
$342.46M
Working capital
$394.47M
Debt to equity
0.21
Current ratio
5.57
Quick ratio
5.47
Net debt/EBITDA
1.11
Margins
Efficiency
Dividend
EBITDA margin
-40.1%
Gross margin
93%
Net margin
-44.9%
Operating margin
-46.7%
Return on assets
-25.7%
Return on equity
-39.7%
Return on invested capital
-39.2%
Return on capital employed
-23.1%
Return on sales
-41%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TARS stock price
How has the Tarsus Pharmaceuticals stock price performed over time
Intraday
-2.87%
1 week
1.43%
1 month
-9.95%
1 year
29.2%
YTD
-22.97%
QTD
-16.97%
Financial performance
How have Tarsus Pharmaceuticals's revenue and profit performed over time
Revenue
$233.67M
Gross profit
$217.29M
Operating income
-$109.17M
Net income
-$104.94M
Gross margin
93%
Net margin
-44.9%
Tarsus Pharmaceuticals's net margin has surged by 87% YoY and by 29% QoQ
Tarsus Pharmaceuticals's operating margin has soared by 87% YoY and by 29% from the previous quarter
TARS's operating income is up by 30% YoY and by 9% QoQ
The company's net income rose by 29% YoY and by 9% QoQ
Price vs fundamentals
How does TARS's price correlate with its fundamentals
Growth
What is Tarsus Pharmaceuticals's growth rate over time
Valuation
What is Tarsus Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.78
P/S
7.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.22
The company's EPS rose by 42% YoY and by 11% QoQ
The company's equity has surged by 53% QoQ and by 24% YoY
TARS's P/B is 33% above its 5-year quarterly average of 3.6 but 22% below its last 4 quarters average of 6.1
The P/S is 62% lower than the 5-year quarterly average of 18.7 and 32% lower than the last 4 quarters average of 10.5
The company's revenue rose by 28% QoQ
Efficiency
How efficient is Tarsus Pharmaceuticals business performance
The company's return on sales has surged by 88% YoY and by 30% QoQ
TARS's return on invested capital has surged by 79% year-on-year and by 26% since the previous quarter
The ROA has soared by 54% YoY and by 18% from the previous quarter
TARS's ROE is up by 44% YoY and by 15% from the previous quarter
Dividends
What is TARS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TARS.
Financial health
How did Tarsus Pharmaceuticals financials performed over time
Tarsus Pharmaceuticals's total liabilities has soared by 114% YoY and by 3.8% from the previous quarter
TARS's total assets is up by 43% year-on-year and by 33% since the previous quarter
Tarsus Pharmaceuticals's debt is 79% lower than its equity
Tarsus Pharmaceuticals's debt has surged by 140% YoY
The debt to equity has soared by 91% YoY but it has contracted by 34% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.